Publication of NT-proBNP patent application

18. Feb 2021 | 1 min read

 

Moss, 18 February 2021

Gentian Diagnostics AS today announces that its patent application for a highly sensitive particle enhanced assay for the quantification of NT-proBNP has been published by the World Intellectual Property Organization (PCT Application No. PCT/EP2020/072720) with WIPO number: WO2021/028520. The technology described in this patent application enables Gentian to develop and commercialize anautomated and fast NT-proBNP assay for open turbidimetric clinical chemistry
platforms.

The launch of the NT-proBNP assay, a biomarker to aid in the diagnosis of congestive heart failure (CHF), is planned for 4Q 2021. The assay under development by Gentian Diagnostics will enable improvement of laboratory productivity based on higher throughput in comparison to currently used assays and contribute to the harmonization and standardization of the NT-proBNP assays.

Going forward, the Company will announce when patents are granted.

For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no  
Cell Phone: +47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no 
Cell Phone. +47 919 06 525


Access the news on Oslo Bors NewsWeb site

You may also read


Jun 25, 2021 - Kristin Hart

Gentian Diagnostics was today listed on the Oslo Stock Exchange

“We made a promise to our shareholders when we were listed on Euronext Growth that we would aim for the main..

Jun 24, 2021 - Kristin Hart

Gentian Diagnostics ASA – Approval and publication of prospectus, and transfer of listing from Euronext Growth (Oslo) to Oslo Børs

Moss, 24 June 2021 Reference is made to the announcement made by Gentian Diagnostics ASA (the "Company") on 7..

Jun 23, 2021 - Kristin Hart

Transfer of shares to Oslo Børs approved, prepared for accelerated growth

Moss, 23.06.2021 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of innovative and..